Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 2Recurrence 1Rectal Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Hodgkin Disease 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 6fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Filgrastim 4Whole-Body Irradiation 3Rituximab 3Etoposide 3Cytarabine 3Carmustine 3Therapeutics 2Tacrolimus 2Saline Solution 2Radiotherapy 2Polymerase Chain Reaction 2Pentetic Acid 2O(6)-benzylguanine 2Methotrexate 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Fibroblast Growth Factor 7 2Dexamethasone 2Busulfan 2sargramostim 1romidepsin 1plerixafor 1pembrolizumab 1merphos 1fludarabine 1ferric pyrophosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Hodgkin Disease × Pyridoxine × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡